‘Made in Chandigarh’ technology to bring down prices of insulin and Hepatitis B vaccine
If everything at the
Presently India has to depend on patented technology of the foreign countries to produce insulin, streptokinase and hepatitis B etc. With 66 million diabetics and 40 million hepatitis B patients in the country, this will be a major reliever for many.
Pichia is the vector that is currently used in insulin.
"Because Pichia is patented, Indian biotech companies have to pay the inventor, which adds to the cost of the vaccine. Thus, we felt the need to develop new expression systems," Dr
Pichia vector is generally licensed for commercial research for $50,000 with annual maintenance fee of $5000 to $30,000. In case the product is commercialized, the fee is $75,000 plus royalty ranging between 3% and 5%.
The present cost of hepatitis B vaccine in India ranges between Rs 45 (
"So far we have expressed hepatitis B vaccine at laboratory scale level in fission yeast. Once the production is scaled up, the production cost is estimated to be around Re 1 per dose, while the lowest production cost reported for Pichia-based system is Rs. 4 per dose and the lowest
- TTD approves Rs 2,938-crore budget for 2021-22
- Wholesale growth expected to continue for tractors, passenger vehicles and two-wheelers, says equity research firm Emkay
- Centre finalises One District One Focus Product to promote in cluster approach
- A Mumbai-based EV startup launched the cheapest electric car with a 200 km range
- HP's worldwide shipments grow 5.6% in fourth quarter of 2020, says IDC